Drug intelligence / Profile preview

KP8051

Development stage: Preclinical
Lead developer: K Pharma
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

KP8051 is an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy under development by **K Pharma, Inc.** for the treatment of **chronic traumatic brain injury (TBI)**. The program is an expansion of K Pharma's lead asset, KP8031, which utilizes similar iPSC-derived neural progenitor cells for spinal cord injury. KP8051 is currently in **preclinical** development in collaboration with the **Osaka Medical Center**. The therapeutic approach involves the transplantation of neural progenitor cells to promote regeneration and functional recovery in the damaged brain tissue of patients in the chronic phase of TBI.

Other names: iPS-derived neural progenitor cellsiPSC-derived neural progenitor cells

Beyond the preview

Go deeper on KP8051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP8051.

Explore the full profile